ASCIA Action Plans for Anaphylaxis and Allergic Reactions
- Should be used as part of a comprehensive anaphylaxis management plan.
- Should be reviewed and reissued when patients are reassessed by their doctor, and each time they obtain a new adrenaline (epinephrine) autoinjector prescription, which is approximately every 12 to 18 months. If there are no changes in diagnosis or management, the medical information may not need to be updated. However, if the patient is a child, the photo should be updated each time, so they can be easily identified.
- Are medical documents and must therefore must be completed and signed by the treating medical or nurse practitioner. To save ASCIA Action Plans that have patient details typed into the text fields you need to "save as" and save with a new name (e.g. patient name).
To access other ASCIA anaphylaxis resources go to www.allergy.org.au/anaphylaxis
For information about how ASCIA information is developed go to www.allergy.org.au/about-ascia/website-informationAn ASCIA Action Plan for Anaphylaxis for use with adrenaline autoinjectors (EpiPen) on airlines is available upon request.
ASCIA Travel Plan and Checklist for people at risk of anaphylaxis
ASCIA Anaphylaxis Checklists
ASCIA Action Plan for Eczema
ASCIA Action Plan for FPIES (food protein-induced enterocolitis syndrome)
ASCIA Action Plan for Hereditary Angioedema (HAE)
ASCIA Treatment Plan for Allergic Rhinitis Treatment Plan
ASCIA Treatment Plan for Sub-Cutaneous Immunotherapy (SCIT)
1. ASCIA Action Plans should be reviewed and reissued when patients are reassessed by their doctor, and each time they obtain a new adrenaline autoinjector prescription, which is approximately every 12 to 18 months. If there are no changes in diagnosis or management the medical information on the ASCIA Action Plan may not need to be updated. However, if the patient is a child, the photo should be updated each time, so they can be easily identified.
2. ASCIA Action Plans for Anaphylaxis can be used for individuals with severe food, medication and insect allergies (ASCIA action plans specific for insect allergy were discontinued in March 2011).
3. ASCIA Action Plans for Anaphylaxis include instructions on how to use an adrenaline autoinjector and should therefore always be stored with the autoinjector.
4. Adrenaline autoinjectors contain a single, fixed dose of adrenaline (they cannot be reused) and are designed to be used by anyone (medical training is not required), including friends, teacher, childcare worker, parents or patients (if they are not too unwell or too young).
5. It is generally recommended that individuals who carry an adrenaline autoinjector should also wear a medical identification emblem such as a MedicAlert emblem www.medicalert.org.au or www.medicalert.co.nz
6. ASCIA Action Plans for Anaphylaxis have been developed as concise and easy to follow, single page documents to assist in emergency treatment of anaphylaxis. These plans should be used as part of a comprehensive anaphylaxis management plan that includes:
- age appropriate education of allergic individuals and their peers or colleagues (patient support organisations have a range of resources to help educate children)
training in the recognition and management of allergic reactions (ASCIA has a range of anaphylaxis e-training courses that can be used for this purpose)
development of strategies to reduce the risk of accidental exposure (refer to ASCIA Guidelines for Anaphylaxis Prevention and patient support organisations)
an emergency response plan for when exposure does occur (ASCIA Action Plans for Anaphylaxis should be used for this purpose).
Webpage updated May 2017